Intraocular use of Lucentis (Ranibizumab) in the treatment of acute central serous chorioretinopathy, an inflammatory diesease of the retina.

Intravitreal Lucentis (Ranibizumab) in acute central serous Chrioretinopathy - a prospective, randomized, single blind monocentric study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-020902-13-AT

Enrollment

Registered

2011-05-18

Start date

2011-07-22

Completion date

Unknown

Last updated

2020-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute central serous chorioretinopathy (CSC) CSC is an acute idiopathic chorioretinopathy. While the majority of cases is characterized by a self-limited course, chronic CSC is seen in up to one third of patients. Case reports and first results of small case series have recently been published about the use of intravitreal bevacizumab with promising results. It is not known if Lucentis (Ranibizumab) may yield same or better results in CSC and prove superior to observation alone.

Interventions

Trade Name: Lucentis Pharmaceutical Form: Injection INN or Proposed INN: RANIBIZUMAB CAS Number: 347396-82-1 Current Sponsor code: ?

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient age >18 a, =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Present ocular, intraocular, or periocular infection Recurrent CSC St.p. intraocular surgery within the past year St.p. Argon laser coagulation of the retina St.p. Photodynamic therapy

Design outcomes

Primary

Measure	Time frame
Main Objective: To test the safety and efficacy of intravitreal injections with Lucentis (Ranibizumab) in acute onset CSC. Primary outcome measure is the resolution of neurosensory detachment as measured my optic coherence tomography six months after study inclusion. ;Secondary Objective: Secondary endpoint is the change of best spectacle-corrected visual acuity as measured by ETDRS vison charts at baseline and six months after inclusion into the study; Primary end point(s): Resolution of neurosensory detachment in OCT scan six months after study inclusion. ;Timepoint(s) of evaluation of this end point: Monthly after study inclusion for six months	—

Measure

Time frame

Main Objective: To test the safety and efficacy of intravitreal injections with Lucentis (Ranibizumab) in acute onset CSC. Primary outcome measure is the resolution of neurosensory detachment as measured my optic coherence tomography six months after study inclusion. ;Secondary Objective: Secondary endpoint is the change of best spectacle-corrected visual acuity as measured by ETDRS vison charts at baseline and six months after inclusion into the study; Primary end point(s): Resolution of neurosensory detachment in OCT scan six months after study inclusion. ;Timepoint(s) of evaluation of this end point: Monthly after study inclusion for six months

—

Secondary

Measure	Time frame
Secondary end point(s): Change in best corrected visual acuity (ETDRS) between first measurement at the time of inclusion and last measurement six months after study inclusion;Timepoint(s) of evaluation of this end point: Monthly after study inclusion for six months	—

Countries

Austria

Contacts

Public ContactRCS Studie, Chefsekretariat

Universitätsklinik für Augenheilkunde und Optometrie, Medizinische Universität Innsbruck

bernhard.steger@i-med.ac.at+4351250423720

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026